DUBLIN--(BUSINESS WIRE)--The "Metabolic Disorder Drugs Market Global Briefing 2018" report has been added to ResearchAndMarkets.com's offering.
Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.
North America was the largest region in the metabolic disorder drugs market in 2016, accounting for around 53% market share. This was mainly due to high prevalence of metabolic syndrome (combination of metabolic diseases including type-2 diabetes) in the USA.
Western Europe was the second largest region accounting for around 16% market share. Asia Pacific was the third largest region accounting for around 15% market share.
Development of New Anti-Diabetic Drugs for Type 2 Diabetes
Drug manufacturers are developing various anti-diabetic drugs for type-2 diabetes treatment.
In July 2017, researchers at the University of California found that Amlexanox, a repurposed asthma drug with anti-inflammatory and anti-allergic properties, can improve blood sugar levels in type 2 diabetic patients.
Similarly, in April 2017, scientists from the Central Drug Research Institute (CDRI) in India had found that chalcone, a plant-derived substance, can be used to produce an anti-diabetic drug that can improve insulin sensitivity and reduce blood glucose levels in patients with type-2 diabetes.
- Markets Covered: Anti-diabetics drugs, Anti-thyroid drugs, and others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism).
- Time Series: Five years historic and forecast.
- Data: Market value in $ billions.
- Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.
- Sanofi S.A.
- Novo Nordisk A/S
- AstraZeneca Plc.
- Johnson & Johnson
- Merck & Co.
- Abbott Laboratories Inc.
- Boehringer Ingelheim GmbH
- AbbVie Inc.
- Takeda Pharmaceuticals
- Pfizer Inc.
- Bayer AG
For more information about this report visit https://www.researchandmarkets.com/research/nrfmb6/metabolic?w=4